Bioceres Q1 Revenue Falls 22%, Net Loss Widens to $10.8M as Liquidity Tightens
BIOX sits 22% above its 52-week low of $0.19 on light trading volume (0.3× avg).
Summary
Revenue fell 22% to $53.8 million and gross profit dropped 39% to $18.8 million, with gross margin collapsing to 35.0% from 44.5%. The net loss from continuing operations widened to $10.8 million from $4.7 million, and Adjusted EBITDA fell to $5.3 million from $13.9 million a year ago. Management blamed delayed soybean seed-treatment sales, a tougher competitive environment in Argentina, and limited financial flexibility that hurt categories needing longer-term financing. The balance sheet is the real problem: cash is down to $8.7 million against $221.7 million of total financial debt, and the full $112 million of secured notes stays classified as short-term after the noteholders' acceleration notices. This lands after the 20-F disclosed substantial doubt about going concern and the Nasdaq bid-price extension to March 15, 2027, so the weak quarter compounds an already fragile capital structure. The one offset is sequential Adjusted EBITDA improvement for a second straight quarter, from negative $0.6 million in 3Q26 to $5.3 million now.
At the time of this announcement, BIOX was trading at $0.23 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $14.8M. The 52-week trading range was $0.19 to $2.03. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.